Skip to main content
. 2019 Aug 8;9:11542. doi: 10.1038/s41598-019-47708-1

Figure 3.

Figure 3

Time to progression for patients with or without two occurrences of temporary increasing ctDNA levels. Patients with multiple occurrences of temporary ctDNA increases have a shorter PFS and OS than patients with stable/decreasing ctDNA levels. For one patient, only C10 and C414 samples were accessible and therefore this patient was excluded from this analysis. (A) Representative patient with one temporary ctDNA increase during the first 60 days of treatment. (B) Representative patient with two instances of temporary ctDNA increases. (C) Progression free survival (PFS). Boxed numbers represents the number of patients in each group not having clinical progression at the given timepoint. (D) Overall survival (OS). Boxed numbers represents the number of patients in each group alive at the indicated timepoint.